
Title:
Lidocaine
Text:
Local anesthetic
.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}LidocaineClinical dataPronunciationLidocaine /ˈlaɪdəˌkeɪn/[1][2]Lignocaine /ˈlɪɡnəˌkeɪn/ Trade namesXylocaine, Ztlido, othersOther nameslignocaineAHFS/Drugs.comLocal Monograph
Systemic Monograph

Ophthalmic Professional Drug FactsMedlinePlusa682701License data
EU EMA: by INN
US DailyMed: Lidocaine
US FDA: Lidocaine
Pregnancycategory
AU: A

Routes ofadministrationIntravenous, subcutaneous, topical, by mouthATC codeC01BB01 (WHO) C05AD01 (WHO) D04AB01 (WHO) N01BB02 (WHO) N01BB52 (WHO) R02AD02 (WHO) S01HA07 (WHO) S02DA01 (WHO) QC01BB01 (WHO) QC05AD01 (WHO) QD04AB01 (WHO) QN01BB02 (WHO) QN01BB52 (WHO) QR02AD02 (WHO) QS01HA07 (WHO) QS02DA01 (WHO) QD04AB51 (WHO)Legal statusLegal status
AU: S5, S4, and S2 [3]
UK: GSL, P, and POM [4]
US: OTC / Rx-only[5][6]
Pharmacokinetic dataBioavailability35% (by mouth)3% (topical)MetabolismLiver,[7] 90% CYP3A4-mediatedOnset of actionwithin 1.5 min (IV)[7]Elimination half-life1.5 h to 2 hDuration of action10 min to 20 min(IV),[7] 0.5 h to 3 h (local)[8][9]ExcretionKidney[7]Identifiers
IUPAC name
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
CAS Number137-58-6 Yas HCl: 73-78-9PubChem CID3676as HCl: 6314IUPHAR/BPS2623DrugBankDB00281 Yas HCl: DBSALT001508ChemSpider3548 Yas HCl: 6075UNII98PI200987as HCl: EC2CNF7XFPKEGGD00358 Yas HCl: D02086 YChEBICHEBI:6456 Yas HCl: CHEBI:50512ChEMBLChEMBL79 Yas HCl: ChEMBL541521PDB ligandLQZ (PDBe, RCSB PDB)CompTox Dashboard (EPA)DTXSID1045166 ECHA InfoCard100.004.821 Chemical and physical dataFormulaC14H22N2OMolar mass234.343 g·mol−13D model (JSmol)Interactive imageMelting point68 °C (154 °F)
SMILES
CCN(CC)CC(=O)NC1=C(C)C=CC=C1C

InChI
InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17) YKey:NNJVILVZKWQKPM-UHFFFAOYSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Lidocaine, also known as lignocaine and sold under the brand name Xylocaine among others, is a local anesthetic of the amino amide type. It is also used to treat ventricular tachycardia.[7][8] When used for local anaesthesia or in nerve blocks, lidocaine typically begins working within several minutes and lasts for half an hour to three hours.[8][9] Lidocaine mixtures may also be applied directly to the skin or mucous membranes to numb the area.[8] It is often used mixed with a small amount of adrenaline (epinephrine) to prolong its local effects and to decrease bleeding.[8]
If injected intravenously, it may cause cerebral effects such as confusion, changes in vision, numbness, tingling, and vomiting.[7] It can cause low blood pressure and an irregular heart rate.[7] There are concerns that injecting it into a joint can cause problems with the cartilage.[8] It appears to be generally safe for use in pregnancy.[7] A lower dose may be required in those with liver problems.[7] It is generally safe to use in those allergic to tetracaine or benzocaine.[8] Lidocaine is an antiarrhythmic medication of the class Ib type.[7] This means it works by blocking sodium channels and thus decreasing the rate of contractions of the heart.[7] When injected near nerves, the nerves cannot conduct signals to or from the brain.[8]
Lidocaine was discovered in 1946 and went on sale in 1948.[10] 
It is on the World Health Organization's List of Essential Medicines.[11] It is available as a generic medication.[8][12] In 2019, it was the 219th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[13][14]

Contents

1 Medical uses

1.1 Local numbing agent
1.2 Heart arrhythmia
1.3 Epilepsy
1.4 Other


2 Adverse effects

2.1 Interactions
2.2 Contraindications
2.3 Overdosage
2.4 Postarthroscopic glenohumeral chondrolysis


3 Pharmacology

3.1 Mechanism of action
3.2 Pharmacokinetics


4 History
5 Society and culture

5.1 Dosage forms
5.2 Names
5.3 Recreational use
5.4 Adulterant in cocaine
5.5 Compendial status


6 Veterinary use
7 See also
8 References
9 External links



Medical uses[edit]
Local numbing agent[edit]
The efficacy profile of lidocaine as a local anaesthetic is characterized by a rapid onset of action and intermediate duration of efficacy. Therefore, lidocaine is suitable for infiltration, block, and surface anaesthesia. Longer-acting substances such as bupivacaine are sometimes given preference for spinal and epidural anaesthesias; lidocaine, though, has the advantage of a rapid onset of action. Adrenaline vasoconstricts arteries, reducing bleeding and also delaying the resorption of lidocaine, almost doubling the duration of anaesthesia.
Lidocaine is one of the most commonly used local anaesthetics in dentistry. It can be administered in multiple ways, most often as a nerve block or infiltration, depending on the type of treatment carried out and the area of the mouth worked on.[15]
For surface anaesthesia, several formulations can be used for endoscopies, before intubations, etc. Buffering the pH of lidocaine makes local numbing less painful.[16] Lidocaine drops can be used on the eyes for short ophthalmic procedures. There is tentative evidence for topical lidocaine for neuropathic pain and skin graft donor site pain.[17][18] As a local numbing agent, it is used for the treatment of premature ejaculation.[19]
An adhesive transdermal patch containing a 5% concentration of lidocaine in a hydrogel bandage, is approved by the US FDA for reducing nerve pain caused by shingles.[20] The transdermal patch is also used for pain from other causes, such as compressed nerves and persistent nerve pain after some surgeries.

Heart arrhythmia[edit]
Lidocaine is also the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated. Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine preventive dose is no longer recommended after a myocardial infarction as the overall benefit is not convincing.[21]

Epilepsy[edit]
A 2013 review on treatment for neonatal seizures recommended intravenous lidocaine as a second-line treatment, if phenobarbital fails to stop seizures.[22]

Other[edit]
Intravenous lidocaine infusions are also used to treat chronic pain and acute surgical pain as an opiate sparing technique. The quality of evidence for this use is poor so it is difficult to compare it to placebo or an epidural.[23]
Inhaled lidocaine can be used as a cough suppressor acting peripherally to reduce the cough reflex. This application can be implemented as a safety and comfort measure for patients who have to be intubated, as it reduces the incidence of coughing and any tracheal damage it might cause when emerging from anaesthesia.[24]
Lidocaine, along with ethanol, ammonia, and acetic acid, may also help in treating jellyfish stings, both numbing the affected area and preventing further nematocyst discharge.[25][26]
For gastritis, drinking a viscous lidocaine formulation may help with the pain.[27]

Adverse effects[edit]
Adverse drug reactions (ADRs) are rare when lidocaine is used as a local anesthetic and is administered correctly. Most ADRs associated with lidocaine for anesthesia relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, and allergic reactions only rarely occur.[28] Systemic exposure to excessive quantities of lidocaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. ADRs by system are:

CNS excitation: nervousness, agitation, anxiety, apprehension, tingling around the mouth (circumoral paraesthesia), headache, hyperesthesia, tremor, dizziness, pupillary changes, psychosis, euphoria, hallucinations, and seizures
CNS depression with increasingly heavier exposure: drowsiness, lethargy, slurred speech, hypoesthesia, confusion, disorientation, loss of consciousness, respiratory depression and apnoea.
Cardiovascular: hypotension, bradycardia, arrhythmias, flushing, venous insufficiency, increased defibrillator threshold, edema, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.[29]
Respiratory: bronchospasm, dyspnea, respiratory depression or arrest
Gastrointestinal: metallic taste, nausea, vomiting
Ears: tinnitus
Eyes: local burning, conjunctival hyperemia, corneal epithelial changes/ulceration, diplopia, visual changes (opacification)
Skin: itching, depigmentation, rash, urticaria, edema, angioedema, bruising, inflammation of the vein at the injection site, irritation of the skin when applied topically
Blood: methemoglobinemia
Allergy
ADRs associated with the use of intravenous lidocaine are similar to toxic effects from systemic exposure above. These are dose-related and more frequent at high infusion rates (≥3 mg/min). Common ADRs include: headache, dizziness, drowsiness, confusion, visual disturbances, tinnitus, tremor, and/or paraesthesia. Infrequent ADRs associated with the use of lidocaine include: hypotension, bradycardia, arrhythmias, cardiac arrest, muscle twitching, seizures, coma, and/or respiratory depression.[29]
It is generally safe to use lidocaine with vasoconstrictor such as adrenaline, including in regions such as the nose, ears, fingers, and toes.[30] While concerns of tissue death if used in these areas have been raised, evidence does not support these concerns.[30]

Interactions[edit]
Any drugs that are also ligands of CYP3A4 and CYP1A2 can potentially increase serum levels and potential for toxicity or decrease serum levels and the efficacy, depending on whether they induce or inhibit the enzymes, respectively. Drugs that may increase the chance of methemoglobinemia should also be considered carefully. Dronedarone and liposomal morphine are both absolutely a contraindication, as they may increase the serum levels, but hundreds of other drugs require monitoring for interaction.[31]

Contraindications[edit]
Absolute contraindications for the use of lidocaine include:

Heart block, second or third degree (without pacemaker)
Severe sinoatrial block (without pacemaker)
Serious adverse drug reaction to lidocaine or amide local anesthetics
Hypersensitivity to corn and corn-related products (corn-derived dextrose is used in the mixed injections)
Concurrent treatment with quinidine, flecainide, disopyramide, procainamide (class I antiarrhythmic agents)
Prior use of amiodarone hydrochloride
Adams-Stokes syndrome[32]
Wolff-Parkinson-White syndrome[32]
Lidocaine viscous is not recommended by the FDA to treat teething pain in children and infants.[33]
Exercise caution in patients with any of these:

Hypotension not due to arrhythmia
Bradycardia
Accelerated idioventricular rhythm
Elderly patients
Ehlers-Danlos Syndrome
Pseudocholinesterase deficiency
Intra-articular infusion (this is not an approved indication and can cause chondrolysis)
Porphyria, especially acute intermittent porphyria; lidocaine has been classified as porphyrogenic because of the hepatic enzymes it induces,[34] although clinical evidence suggests it is not.[35] Bupivacaine is a safe alternative in this case.
Impaired liver function – people with lowered hepatic function may have an adverse reaction with repeated administration of lidocaine because the drug is metabolized by the liver. Adverse reactions may include neurological symptoms (e.g. dizziness, nausea, muscle twitches, vomiting, or seizures).[36]
Overdosage[edit]
Overdoses of lidocaine may result from excessive administration by topical or parenteral routes, accidental oral ingestion of topical preparations by children (who are more susceptible to overdose), accidental intravenous (rather than subcutaneous, intrathecal, or paracervical) injection, or from prolonged use of subcutaneous infiltration anesthesia during cosmetic surgery.
Such overdoses have often led to severe toxicity or death in both children and adults. Lidocaine and its two major metabolites may be quantified in blood, plasma, or serum to confirm the diagnosis in potential poisoning victims or to assist forensic investigation in a case of fatal overdose.
Lidocaine is often given intravenously as an antiarrhythmic agent in critical cardiac-care situations.[37] Treatment with intravenous lipid emulsions (used for parenteral feeding) to reverse the effects of local anaesthetic toxicity is becoming more common.[38]

Postarthroscopic glenohumeral chondrolysis[edit]
Lidocaine in large amounts may be toxic to cartilage and intra-articular infusions can lead to postarthroscopic glenohumeral chondrolysis.[39]

Pharmacology[edit]
Mechanism of action[edit]
Lidocaine alters signal conduction in neurons by prolonging the inactivation of the fast voltage-gated Na+ channels in the neuronal cell membrane responsible for action potential propagation.[40] With sufficient blockage, the voltage-gated sodium channels will not open and an action potential will not be generated. Careful titration allows for a high degree of selectivity in the blockage of sensory neurons, whereas higher concentrations also affect other types of neurons.
The same principle applies for this drug's actions in the heart. Blocking sodium channels in the conduction system, as well as the muscle cells of the heart, raises the depolarization threshold, making the heart less likely to initiate or conduct early action potentials that may cause an arrhythmia.[41]

Pharmacokinetics[edit]
When used as an injectable it typically begins working within four minutes and lasts for half an hour to three hours.[8][9] Lidocaine is about 95% metabolized (dealkylated) in the liver mainly by CYP3A4 to the pharmacologically active metabolites monoethylglycinexylidide (MEGX) and then subsequently to the inactive glycine xylidide. MEGX has a longer half-life than lidocaine, but also is a less potent sodium channel blocker.[42] The volume of distribution is 1.1 L/kg to 2.1 L/kg, but congestive heart failure can decrease it. About 60% to 80% circulates bound to the protein alpha1 acid glycoprotein. The oral bioavailability is 35% and the topical bioavailability is 3%.
The elimination half-life of lidocaine is biphasic and around 90 min to 120 min in most patients. This may be prolonged in patients with hepatic impairment (average 343 min) or congestive heart failure (average 136 min).[43] Lidocaine is excreted in the urine (90% as metabolites and 10% as unchanged drug).[44]

History[edit]
Lidocaine, the first amino amide–type local anesthetic, was first synthesized under the name 'xylocaine' by Swedish chemist Nils Löfgren in 1943.[45][46][47] His colleague Bengt Lundqvist performed the first injection anesthesia experiments on himself.[45] It was first marketed in 1949.

Society and culture[edit]
Dosage forms[edit]
Lidocaine, usually in the form of its hydrochloride salt, is available in various forms including many topical formulations and solutions for injection or infusion.[48]  It is also available as a transdermal patch, which is applied directly to the skin.


		
			
			
Lidocaine hydrochloride 2% epinephrine 1:80,000 solution for injection in a cartridge

			
		
		
			
			
Lidocaine hydrochloride 1% solution for injection

			
		
		
			
			
Topical lidocaine spray

			
		
		
			
			
2% viscous lidocaine

			
		

Names[edit]
Lidocaine is the International Nonproprietary Name (INN), British Approved Name (BAN), and Australian Approved Name (AAN),[49] while lignocaine is the former BAN[citation needed] and AAN. Both the old and new names will be displayed on the product label in Australia until at least 2023.[50]
Xylocaine is a brand name.

Recreational use[edit]
As of 2021,[update] lidocaine is not listed by the World Anti-Doping Agency as a substance whose use is banned in sport.[51] It is used as an adjuvant, adulterant, and diluent to street drugs such as cocaine and heroin.[52] It is one of the three common ingredients in site enhancement oil used by bodybuilders.[53]

Adulterant in cocaine[edit]
Lidocaine is often added to cocaine as a diluent.[54][55] Cocaine and lidocaine both numb the gums when applied. This gives the user the impression of high-quality cocaine, when in actuality the user is receiving a diluted product.[56]

Compendial status[edit]
Japanese Pharmacopoeia 15
United States Pharmacopeia 31[57]
Veterinary use[edit]
It is a component of the veterinary drug Tributame along with embutramide and chloroquine used to carry out euthanasia on horses and dogs.[58][59]

See also[edit]
Dimethocaine (has some DRI activity)
Lidocaine/prilocaine
Procaine
Mexiletine
References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Lidocaine". Merriam-Webster Dictionary.

^ "Lidocaine". Dictionary.com Unabridged. Random House.

^ "Poisons Standard February 2021". Federal Register of Legislation. 1 January 2021. Retrieved 11 April 2021.

^ "Lidocaine Hydrochloride Injection BP 1% w/v - Summary of Product Characteristics (SmPC)". (emc). 29 June 2020. Retrieved 11 April 2021.

^ "Xylocaine MPF- lidocaine hydrochloride injection, solution Xylocaine- lidocaine hydrochloride injection, solution Xylocaine- lidocaine hydrochloride,epinephrine bitartrate injection, solution". DailyMed. Retrieved 11 April 2021.

^ "Ztlido- lidocaine patch". DailyMed. Retrieved 11 April 2021.

^ a b c d e f g h i j k "Lidocaine Hydrochloride (Antiarrhythmic)". The American Society of Health-System Pharmacists. Archived from the original on 2015-08-10. Retrieved Aug 26, 2015.

^ a b c d e f g h i j "Lidocaine Hydrochloride (Local)". The American Society of Health-System Pharmacists. Archived from the original on 2015-09-06. Retrieved Aug 26, 2015.

^ a b c J. P. Nolan; P. J. F. Baskett (1997). "Analgesia and anaesthesia".  In David Skinner; Andrew Swain; Rodney Peyton; Colin Robertson (eds.). Cambridge Textbook of Accident and Emergency Medicine. Project co-ordinator, Fiona Whinster. Cambridge, UK: Cambridge University Press. p. 194. ISBN 9780521433792. Archived from the original on 2017-09-08.

^ Scriabine, Alexander (1999). "Discovery and development of major drugs currently in use".  In Ralph Landau; Basil Achilladelis; Alexander Scriabine (eds.). Pharmaceutical Innovation: Revolutionizing Human Health. Philadelphia: Chemical Heritage Press. p. 211. ISBN 9780941901215. Archived from the original on 2017-09-08.

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06.

^ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 22. ISBN 9781284057560.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Lidocaine - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ "Local anaesthetic drugs".

^ Cepeda MS, Tzortzopoulou A, Thackrey M, Hudcova J, Arora Gandhi P, Schumann R (December 2010).  Tzortzopoulou A (ed.). "Adjusting the pH of lidocaine for reducing pain on injection". The Cochrane Database of Systematic Reviews (12): CD006581. doi:10.1002/14651858.CD006581.pub2. PMID 21154371.  (Retracted, see doi:10.1002/14651858.cd006581.pub3. If this is an intentional citation to a retracted paper, please replace {{Retracted}} with {{Retracted|intentional=yes}}.)

^ Derry S, Wiffen PJ, Moore RA, Quinlan J (July 2014).  Derry S (ed.). "Topical lidocaine for neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 7 (7): CD010958. doi:10.1002/14651858.CD010958.pub2. PMC 6540846. PMID 25058164.

^ Sinha S, Schreiner AJ, Biernaskie J, Nickerson D, Gabriel VA (November 2017). "Treating pain on skin graft donor sites: Review and clinical recommendations". The Journal of Trauma and Acute Care Surgery. 83 (5): 954–964. doi:10.1097/TA.0000000000001615. PMID 28598907. S2CID 44520644.

^ "Lidocaine/prilocaine spray for premature ejaculation". Drug and Therapeutics Bulletin. 55 (4): 45–48. April 2017. doi:10.1136/dtb.2017.4.0469. PMID 28408390. S2CID 19110955.

^ Kumar M, Chawla R, Goyal M (2015). "Topical anesthesia". Journal of Anaesthesiology Clinical Pharmacology. 31 (4): 450–6. doi:10.4103/0970-9185.169049. PMC 4676230. PMID 26702198.

^ Martí-Carvajal AJ, Simancas-Racines D, Anand V, Bangdiwala S (August 2015). "Prophylactic lidocaine for myocardial infarction". The Cochrane Database of Systematic Reviews. 8 (8): CD008553. doi:10.1002/14651858.CD008553.pub2. PMC 8454263. PMID 26295202.

^ Slaughter LA, Patel AD, Slaughter JL (March 2013). "Pharmacological treatment of neonatal seizures: a systematic review". Journal of Child Neurology. 28 (3): 351–64. doi:10.1177/0883073812470734. PMC 3805825. PMID 23318696.

^ Weibel S, Jelting Y, Pace NL, Helf A, Eberhart LH, Hahnenkamp K,  et al. (June 2018). "Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults". The Cochrane Database of Systematic Reviews. 2018 (6): CD009642. doi:10.1002/14651858.cd009642.pub3. PMC 6513586. PMID 29864216.

^ Biller JA (2007). "Airway obstruction, bronchospasm, and cough".  In Berger AM, Shuster JL, Von Roenn JH (eds.). Principles and practice of palliative care and supportive oncology. Hagerstwon, MD: Lippincott Williams & Wilkins. pp. 297–307. ISBN 978-0-7817-9595-1. Inhaled lidocaine is used to suppress cough during bronchoscopy. Animal studies and a few human studies suggest that lidocaine has an antitussive effect…

^ Birsa LM, Verity PG, Lee RF (May 2010). "Evaluation of the effects of various chemicals on discharge of and pain caused by jellyfish nematocysts". Comp. Biochem. Physiol. C. 151 (4): 426–30. doi:10.1016/j.cbpc.2010.01.007. PMID 20116454.

^ Morabito R, Marino A, Dossena S, La Spada G (Jun 2014). "Nematocyst discharge in Pelagia noctiluca (Cnidaria, Scyphozoa) oral arms can be affected by lidocaine, ethanol, ammonia and acetic acid". Toxicon. 83: 52–8. doi:10.1016/j.toxicon.2014.03.002. PMID 24637105.

^ James G. Adams (2012). "32". Emergency Medicine: Clinical Essentials. Elsevier Health Sciences. ISBN 9781455733941. Archived from the original on 2017-09-08.

^ Jackson D, Chen AH, Bennett CR (October 1994). "Identifying true lidocaine allergy". J Am Dent Assoc. 125 (10): 1362–6. doi:10.14219/jada.archive.1994.0180. PMID 7844301.

^ a b Australian Medicines Handbook. Adelaide, S. Aust: Australian Medicines Handbook Pty Ltd. 2006. ISBN 978-0-9757919-2-9.[page needed]

^ a b Nielsen LJ, Lumholt P, Hölmich LR (October 2014). "[Local anaesthesia with vasoconstrictor is safe to use in areas with end-arteries in fingers, toes, noses and ears]". Ugeskrift for Laeger. 176 (44). PMID 25354008.

^ "Lidocaine". Epocrates. Archived from the original on 2014-04-22.

^ a b "Lidocaine Hydrochloride and 5% Dextrose Injection". Safety Labeling Changes. FDA Center for Drug Evaluation and Research (CDER). January 2014. Archived from the original on 2013-04-03.

^ "Lidocaine Viscous: Drug Safety Communication - Boxed Warning Required - Should Not Be Used to Treat Teething Pain". FDA Center for Drug Evaluation and Research (CDER). June 2014. Archived from the original on 2014-07-14.

^ "Table 96–4. Drugs and Porphyria" (PDF). Merck Manual. Merck & Company, Inc. 2011. Archived from the original on 2014-04-20.

^ "Lidocaine - N01BB02". Drug porphyrinogenicity monograph. The Norwegian Porphyria Centre and the Swedish Porphyria Centre. Archived from the original on 2014-04-20. strong clinical evidence points to lidocaine as probably not porphyrinogenic

^ Khan, M. Gabriel (2007). Cardiac Drug Therapy (7th ed.). Totowa, NJ: Humana Press. ISBN 9781597452380.

^ Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 840–4. ISBN 978-0-9626523-7-0.

^ Picard J, Ward SC, Zumpe R, Meek T, Barlow J, Harrop-Griffiths W (February 2009). "Guidelines and the adoption of 'lipid rescue' therapy for local anaesthetic toxicity". Anaesthesia. 64 (2): 122–5. doi:10.1111/j.1365-2044.2008.05816.x. PMID 19143686. S2CID 25581037.

^ Gulihar A, Robati S, Twaij H, Salih A, Taylor GJ (December 2015). "Articular cartilage and local anaesthetic: A systematic review of the current literature". Journal of Orthopaedics. 12 (Suppl 2): S200-10. doi:10.1016/j.jor.2015.10.005. PMC 4796530. PMID 27047224.

^ Carterall, William A. (2001). "Molecular mechanisms of gating and drug block of sodium channels". Sodium Channels and Neuronal Hyperexcitability. Novartis Foundation Symposia. Vol. 241. pp. 206–225. doi:10.1002/0470846682.ch14. ISBN 9780470846681.

^ Sheu SS, Lederer WJ (Oct 1985). "Lidocaine's negative inotropic and antiarrhythmic actions. Dependence on shortening of action potential duration and reduction of intracellular sodium activity". Circulation Research. 57 (4): 578–90. doi:10.1161/01.res.57.4.578. PMID 2412723.

^ Lewin NA, Nelson LH (2006). "Chapter 61: Antidysrhythmics".  In Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA, Nelson LH (eds.). Goldfrank's Toxicologic Emergencies (8th ed.). New York: McGraw-Hill. pp. 963–4. ISBN 978-0-07-143763-9.

^ Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M (April 1973). "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans". Ann. Intern. Med. 78 (4): 499–508. doi:10.7326/0003-4819-78-4-499. PMID 4694036.

^ Collinsworth KA, Kalman SM, Harrison DC (1974). "The clinical pharmacology of lidocaine as an antiarrhythymic drug". Circulation. 50 (6): 1217–30. doi:10.1161/01.CIR.50.6.1217. PMID 4609637.

^ a b Löfgren N (1948). Studies on local anesthetics: Xylocaine: a new synthetic drug (Inaugural dissertation). Stockholm, Sweden: Ivar Heggstroms. OCLC 646046738.[page needed]

^ Löfgren N, Lundqvist B (1946). "Studies on local anaesthetics II". Svensk Kemisk Tidskrift. 58: 206–17.

^ Wildsmith JAW (2011). "Lidocaine: A more complex story than 'simple' chemistry suggests" (PDF). The Proceedings of the History of Anaesthesia Society. 43: 9–16. Archived (PDF) from the original on 2014-04-22.

^ "Lidocaine international forms and names". Drugs.com. Retrieved 29 October 2017.

^ "Lidocaine Ingredient Summary". Therapeutic Goods Administration. Retrieved 20 September 2018.

^ "Updating medicine ingredient names - list of affected ingredients". Therapeutic Goods Administration. 24 June 2019. Retrieved 16 February 2020.

^ "The 2021 Prohibited List International Standard" (PDF). The World Anti-Doping Code. World Anti-Doping Agency (WADA). 1 January 2021. Archived from the original (PDF) on 13 May 2021. Retrieved 18 May 2021.

^ "New York Drug Threat Assessment". National Drug Intelligence Center. November 2002. Archived from the original on 2012-08-12.

^ Pupka A, Sikora J, Mauricz J, Cios D, Płonek T (2009). "[The usage of synthol in the body building]". Polimery W Medycynie. 39 (1): 63–5. PMID 19580174.

^ Bernardo NP; Siqueira MEPB; De Paiva MJN; Maia PP (2003). "Caffeine and other adulterants in seizures of street cocaine in Brazil". International Journal of Drug Policy. 14 (4): 331–4. doi:10.1016/S0955-3959(03)00083-5.

^ "UNITED STATES of America, Plaintiff-Appellee, v. Luis A. CUELLO, Alvaro Bastides-Benitez, John Doe, a/k/a Hugo Hurtado, and Alvaro Carvajal, Defendants-Appellants". Docket No. 78-5314. United States Court of Appeals, Fifth Circuit. 1979-07-25. Archived from the original on 2012-05-24.

^ Winterman, Denise (2010-09-07). "How cutting drugs became big business". BBC News Online. BBC News Magazine. Archived from the original on 2 February 2017. Retrieved 20 January 2017.

^ "Revision Bulletin: Lidocaine and Prilocaine Cream–Revision to Related Compounds Test". The United States Pharmacopeial Convention. November 30, 2007. Archived from the original on May 1, 2013.

^ Peterson, Michael E.; Talcott, Patricia A. (2013-08-07). Small Animal Toxicology. Elsevier Health Sciences. ISBN 978-0323241984. Archived from the original on 2017-09-08.

^ "FDA Freedom of Information Summary - Tributame" (PDF). Food and Drug Administration. Archived from the original (PDF) on 2015-05-18.


External links[edit]
"Lidocaine". Drug Information Portal. U.S. National Library of Medicine.
"Lidocaine Transdermal Patch". MedlinePlus.
.mw-parser-output .citation{word-wrap:break-word}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}US patent 2441498, Nils Magnus Loefgren & Bengt Josef Lundqvist, "Alkyl glycinanilides", published 1948-05-11, issued 1948-05-11,  assigned to ASTRA APOTEKARNES KEM FAB 
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteAntiarrhythmic agents (C01B)Channel blockersclass I(Na+ channel blockers)class Ia (Phase 0→ and Phase 3→)
Ajmaline
Disopyramide
Hydroquinidine
Lorajmine
Prajmaline
Procainamide#
Quinidine#
Sparteine
class Ib (Phase 3←)
IV
Lidocaine#
enteral
Aprindine
Mexiletine
Tocainide
class Ic (Phase 0→)
Encainide‡
Ethacizine
Flecainide
Indecainide‡
Lorcainide
Moracizine‡
Propafenone
class III(Phase 3→, K+ channel blockers)
Amiodarone
Bretylium
Bunaftine
Celivarone†
Dofetilide
Dronedarone
E-4031†
Ibutilide
Nifekalant
Sotalol
Tedisamil
Vernakalant
class IV(Phase 4→, Ca2+ channel blockers)
Diltiazem
Verapamil#
Receptor agonistsand antagonistsclass II(Phase 4→, β blockers)
Nadolol
Pindolol
Propranolol
cardioselective
Acebutolol
Atenolol
Esmolol
Metoprolol
A1 agonist
Adenosine
Benzodiazepines
Barbiturates
M2
muscarinic antagonist: Atropine
Disopyramide
Quinidinemuscarinic agonist: Digoxin
α receptors
Amiodarone
Bretylium
Quinidine
Verapamil
Ion transportersNa+/ K+-ATPase
Digitoxin
Digoxin
Ouabain

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteVasoprotectives (C05)Antihemorrhoidals for topical usecorticosteroids
Hydrocortisone
Prednisolone
Betamethasone
Fluorometholone
Fluocortolone
Dexamethasone
Fluocinolone acetonide
Fluocinonide
local anesthetics
Lidocaine
Tetracaine
Benzocaine
Dibucaine
Procaine
Oxetacaine
Pramocaine
other
Tribenoside
Antivaricose therapyheparins or heparinoids for topical use
Organo-heparinoid
Sodium apolate
Heparin
Pentosan polysulfate
sclerosing agents for local injection
Monoethanolamine oleate
Polidocanol
Inverted sugar syrup
Sodium tetradecyl sulfate
Phenol
other
Calcium dobesilate
Capillary stabilising agentsbioflavonoids
Rutoside
Monoxerutin
Diosmin
Troxerutin
Hidrosmin
other
Tribenoside
Etamsylate

vteAntipruritics (D04)Antihistamines for topical use
Thonzylamine
Mepyramine
Thenalidine
Tripelennamine
Chloropyramine
Promethazine
Tolpropamine
Dimetindene
Clemastine
Bamipine
Isothipendyl
Diphenhydramine
Chlorphenoxamine
Anesthetics for topical use
Lidocaine
Dibucaine
Oxybuprocaine
Benzocaine
Quinisocaine
Tetracaine
Pramocaine
Others
Corticosteroids (e.g., hydrocortisone)
Counterirritants (e.g., mint oil, menthol, camphor)
Difelikefalin
Nalfurafine

vteLocal anesthetics (primarily sodium channel blockers) (N01B)Esters by acidAminobenzoic
Benzocaine
Butacaine
Butamben
Chloroprocaine
Dimethocaine
Lucaine
Meprylcaine
Metabutethamine
Metabutoxycaine
Nitracaine
Orthocaine
Propoxycaine
Procaine (Novocaine)
Proxymetacaine
Risocaine
Tetracaine
Benzoic
Amylocaine
Cocaine
Cyclomethycaine
α-Eucaine
β-Eucaine
Hexylcaine
Isobucaine
Piperocaine
ArCO2- (not para-amino or Ph)
Amoproxan (3,4,5-Trimethoxybenzoyl)
3-(p-Fluorobenzoyloxy)tropane
Amides
Articaine
Bupivacaine#/Levobupivacaine/Ropivacaine
Butanilicaine
Carticaine
 Cinchocaine (Dibucaine)
Etidocaine
Lidocaine#
Mepivacaine
Prilocaine
Trimecaine
Combinations
Anesthetic/vasoconstrictor
Bupivacaine/meloxicam
Lidocaine/prilocaine
TAC
Iontocaine

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteNeuropathic pain and fibromyalgia pharmacotherapiesMonoaminergics
SNRIs (e.g., duloxetine, milnacipran)
TCAs (e.g., amitriptyline, nortriptyline, dosulepin)
Opioid MRIs (e.g., tapentadol, tramadol)
Ion channel blockers
Anticonvulsants (e.g., gabapentin, pregabalin, mirogabalin, carbamazepine, oxcarbazepine, lacosamide, lamotrigine)
Local anesthetics (e.g., lidocaine)
Mexiletine
TCAs (e.g., amitriptyline, nortriptyline, desipramine)
Ziconotide
Others
Alpha lipoic acid
Benfotiamine
Botulinum toxin A
Bupropion
Cannabinoids (e.g., cannabis, dronabinol, nabilone)
NMDA receptor antagonists (e.g., ketamine, dextromethorphan, methadone)
Opioids (e.g., hydrocodone, morphine, oxycodone, methadone, buprenorphine, tramadol, tapentadol)
Sodium oxybate (GHB)

vteThroat preparations (R02)Antiseptics
Acriflavinium chloride
Ambazone
Amylmetacresol
Benzalkonium
Benzethonium
Cetrimonium (bromide/chloride)
Cetylpyridinium
Chlorhexidine
Chlorquinaldol
Dequalinium
Dichlorobenzyl alcohol
Hexamidine
Hexetidine
Hexylresorcinol
Myristyl-benzalkonium
Oxyquinoline
Phenol
Povidone-iodine
Antibiotics
Bacitracin
Fusafungine
Gramicidin
Neomycin
Tyrothricin
Local anesthetics
Benzocaine
Cocaine
Dyclonine
Lidocaine
Other
Flurbiprofen

vteDrugs used for diseases of the ear (S02)Infection
Acetic acid
Aluminium acetotartrate
Aluminium triacetate (Burow's solution)
Boric acid
Chloramphenicol
Chlorhexidine
Ciprofloxacin
Clioquinol
Gentamicin
Hydrogen peroxide
Miconazole
Neomycin
Nitrofurazone
Ofloxacin
Polymyxin B
Rifamycin
Tetracycline
Corticosteroids
Betamethasone
Dexamethasone
Fluocinolone acetonide
Hydrocortisone
Prednisolone
Analgesics and anesthetics
Lidocaine
Cocaine
Phenazone

vteIon channel modulatorsCalciumVDCCsBlockers
L-type-selective: Dihydropyridines: Amlodipine
Aranidipine
Azelnidipine
Barnidipine
Clevidipine
Cronidipine
Darodipine
Dexniguldipine
Elgodipine
Elnadipine
Felodipine
Flordipine
Furnidipine
Iganidipine
Isradipine
Lacidipine
Lemildipine
Lercanidipine
Levamlodipine
Levniguldipine
Manidipine
Mepirodipine
Mesudipine
Nicardipine
Nifedipine
Niguldipine
Niludipine
Nilvadipine
Nimodipine
Nisoldipine
Nitrendipine
Olradipine
Oxodipine
Palonidipine
Pranidipine
Ryodipine (riodipine)
Sagandipine
Sornidipine
Teludipine
Tiamdipine
Trombodipine
Vatanidipine; Diltiazem derivatives: Clentiazem
Diltiazem
Iprotiazem
Nictiazem
Siratiazem; Phenylalkylamines: Anipamil
Dagapamil
Devapamil
Dexverapamil
Emopamil
Etripamil
Falipamil
Gallopamil
Levemopamil
Nexopamil
Norverapamil
Ronipamil
Tiapamil
Verapamil; Others: AH-1058
Brinazarone
Budiodarone
Celivarone
Cyproheptadine
Dronedarone
Fantofarone
SR-33805
Tetrahydropalmatine
N-type-selective: ω-Conotoxins
ω-Conotoxin GVIA
Caroverine
Huwentoxin XVI
Leconotide (ω-conotoxin CVID)
PD-173212
Ralfinamide
Safinamide
Z160
Ziconotide (ω-conotoxin MVIIA)
P-type-selective: ω-Agatoxin IVA
ω-Agatoxin IVB
R-type-selective: SNX-482
T-type-selective: ABT-639
ML-218
Niflumic acid
NNC 55-0396
ProTx I
Z944
Zonisamide
Non-selective: ω-Agatoxin TK
ω-Conotoxin MVIIC
Benidipine
Bepridil
Cilnidipine
Cinnarizine
Dotarizine
Efonidipine
Flunarizine
Lamotrigine
Levetiracetam
Lomerizine
Loperamide
Mibefradil
NP078585
Ruthenium red
TROX-1
α2δ subunit-selective (gabapentinoids): 4-Methylpregabalin
Arbaclofen
Arbaclofen placarbil
Atagabalin
Baclofen
Gabapentin
Gabapentin enacarbil
Imagabalin
Mirogabalin
PD-200,347
PD-217,014
PD-299,685
Phenibut
Pregabalin
Others/unsorted: Bencyclane
Berbamine
Bevantolol
Canadine
Carboxyamidotriazole
Cycleanine
Dauricine
Dimeditiapramine
Diproteverine
Enpiperate
Eperisone
Elpetrigine
Ethadione
Ethanol (alcohol)
Ethosuximide
Fasudil
Fendiline
Fostedil
Imepitoin
JTV-519
Lidoflazine
Magnesium
Manoalide
Mesuximide
Monatepil
Naftopidil
Ochratoxin A
Osthol
Otilonium bromide
Paramethadione
Phensuximide
Pinaverium bromide
Prenylamine
Rhynchophylline
Sesamodil
Silperisone
Sipatrigine
Terodiline
Tetrandrine
Tolperisone
Trimethadione
Valperinol
Activators
L-type-selective: Bay K8644
PotassiumVGKCsBlockers
3,4-Diaminopyridine (amifampridine)
4-Aminopyridine (fampridine/dalfampridine)
Adekalant
Almokalant
Amiodarone
Azimilide
Bretylium
Bunaftine
Charybdotoxin
Clamikalant
Conotoxins
Dalazatide
Dendrotoxin
Dofetilide
Dronedarone
E-4031
Hanatoxin
HgeTx1
HsTx1
Ibutilide
Inakalant
Kaliotoxin
Linopirdine
Lolitrem B
Maurotoxin
Nifekalant
Notoxin
Paxilline
Pinokalant
Quinidine
ShK-186
Sotalol
Tedisamil
Terikalant
Tetraethylammonium
Vernakalant
hERG (KCNH2, Kv11.1)-specific: Ajmaline
Amiodarone
AmmTX3
Astemizole
Azaspiracid
AZD1305
Azimilide
Bedaquiline
BeKm-1
BmTx3
BRL-32872
Chlorpromazine
Cisapride
Clarithromycin
Darifenacin
Dextropropoxyphene
Diallyl trisulfide
Domperidone
E-4031
Ergtoxins
Erythromycin
Gigactonine
Haloperidol
Ketoconazole
Norpropoxyphene
Orphenadrine
Pimozide
PNU-282,987
Promethazine
Quinidine
Ranolazine
Roxithromycin
Sertindole
Solifenacin
Tamulotoxin
Terodiline
Terfenadine
Thioridazine
Tolterodine
Vanoxerine
Vernakalant
KCNQ (Kv7)-specific: Linopirdine
XE-991
Spooky toxin (SsTx)
Activators
KCNQ (Kv7)-specific: Flupirtine
Retigabine
IRKsBlockers
KATP-specific: Acetohexamide
Carbutamide
Chlorpropamide
Glibenclamide (glyburide)
Glibornuride
Glicaramide
Gliclazide
Glimepiride
Glipizide
Gliquidone
Glisoxepide
Glyclopyramide
Glycyclamide
Metahexamide
Mitiglinide
Nateglinide
Repaglinide
Tolazamide
Tolbutamide
GIRK-specific: Barium
Caramiphen
Cloperastine
Clozapine
Dextromethorphan
Ethosuximide
Ifenprodil
Tertiapin
Tipepidine
Activators
KATP-specific: Aprikalim
Bimakalim
Cromakalim
Diazoxide
Emakalim
Levcromakalim
Mazokalim
Minoxidil
Naminidil
Nicorandil
Pinacidil
Rilmakalim
Sarakalim
GIRK-specific: ML-297 (VU0456810)
KCaBlockers
BKCa-specific: Ethanol (alcohol)
GAL-021
Activators
BKCa-specific: Flufenamic acid
Meclofenamic acid
Niflumic acid
Nimesulide
Rottlerin (mallotoxin)
Tolfenamic acid
K2PsBlockers
12-O-Tetradecanoylphorbol-13-acetate
Arachidonic acid
Fluoxetine
Norfluoxetine
Activators
Riluzole
SodiumVGSCsBlockers
Antianginals: Ranolazine
Antiarrhythmics (class I): Ajmaline
Aprindine
Disopyramide
Dronedarone
Encainide
Flecainide
Lidocaine
Lorajmine
Lorcainide
Mexiletine
Moricizine
Pilsicainide
Prajmaline
Procainamide
Propafenone
Quinidine
Sparteine
Tocainide
Anticonvulsants: Acetylpheneturide
Carbamazepine
Cenobamate
Chlorphenacemide
Elpetrigine
Eslicarbazepine acetate
Ethotoin
Fosphenytoin
Lacosamide
Licarbazepine
Mephenytoin
Oxcarbazepine
Oxitriptyline
Phenacemide
Pheneturide
Phenytoin
Rufinamide
Sipatrigine
Topiramate
Sodium valproate
Valnoctamide
Valproate pivoxil
Valproate semisodium
Valproic acid
Valpromide
Zonisamide
Local anesthetics: pFBT
Amylocaine
Articaine
Benzocaine
Bupivacaine (Levobupivacaine, Ropivacaine)
Butacaine
Butamben
Chloroprocaine
Cinchocaine
Cocaine
Cyclomethycaine
Dimethocaine
Diphenhydramine
Etidocaine
Hexylcaine
Iontocaine
Lidocaine
Mepivacaine
Meprylcaine
Metabutoxycaine
Orthocaine
Piperocaine
Prilocaine
Procaine
Propoxycaine
Proxymetacaine
Risocaine
Tetracaine
Trimecaine
Analgesics: AZD-3161
DSP-2230
Funapide
GDC-0276
NKTR-171
PF-04531083
PF-05089771
Ralfinamide
Raxatrigine
RG7893 (GDC-0287)
Toxins: Conotoxins
Neosaxitoxin
Saxitoxin
Tetrodotoxin
Zetekitoxin AB
Others: Buprenorphine
Evenamide
Menthol (mint)
Safinamide
Tricyclic antidepressants
Activators
Aconitine
Atracotoxins (ω-Atracotoxin, Robustoxin, Versutoxin)
Batrachotoxin
Ciguatoxins
Grayanotoxins
Poneratoxin
ENaCBlockers
Amiloride
Benzamil
Triamterene
Activators
Solnatide
ASICsBlockers
A-317567
Amiloride
Aspirin
Ibuprofen
PcTX1
ChlorideCaCCsBlockers
Crofelemer
DIDS
Ethacrynic acid
Flufenamic acid
Fluoxetine
Furosemide
Glibenclamide
Mefloquine
Mibefradil
Niflumic acid
Activators
Carbachol
CFTRBlockers
Glibenclamide
Lonidamine
Piretanide
Activators
1,7-Phenanthroline
1,10-Phenanthroline
4,7-Phenanthroline
7,8-Benzoquinoline
Ivacaftor
Phenanthridine
UnsortedBlockers
Bumetanide
Flufenamic acid
Meclofenamic acid
Mefenamic acid
Mepacrine
Niflumic acid
Talniflumate
Tolfenamic acid
Trifluoperazine
OthersTRPs
See here instead.
LGICs
See here instead.
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





